|
|
Volumn 7, Issue 5, 2003, Pages 521-528
|
|
Understanding novel therapeutic agents for multiple myeloma.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ARSENIC TRIOXIDE;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
DRUG DERIVATIVE;
IMMUNOLOGICAL ADJUVANT;
LENALIDOMIDE;
ORGANOARSENIC DERIVATIVE;
OXIDE;
PROTEINASE INHIBITOR;
PYRAZINE DERIVATIVE;
THALIDOMIDE;
ANIMAL;
CLINICAL TRIAL;
DRUG SCREENING;
HUMAN;
METHODOLOGY;
MORTALITY;
MULTIPLE MYELOMA;
REMISSION;
REVIEW;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADJUVANTS, IMMUNOLOGIC;
ANIMALS;
ANTINEOPLASTIC AGENTS;
ARSENICALS;
BORONIC ACIDS;
CLINICAL TRIALS;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
MULTIPLE MYELOMA;
OXIDES;
PROTEASE INHIBITORS;
PYRAZINES;
REMISSION INDUCTION;
RESEARCH DESIGN;
SURVIVAL RATE;
THALIDOMIDE;
TREATMENT OUTCOME;
|
|
EID: 0642347797
PISSN: 10921095
EISSN: None
Source Type: Journal
DOI: 10.1188/03.CJON.521-528 Document Type: Review |
|
Times cited : (7)
|
|
References (68)
|
